Enhua Pharmaceutical: Clinical trials for NH130 tablets and NH302 injection approved

On August 18, Enhua Pharmaceutical announced that it recently received the "Drug Clinical Trial Approval Notice" for its innovative Class 1 drug NH130 citrate tablets, granting permission to conduct clinical trials. The intended indications are: planned for the treatment of schizophrenia; planned for the treatment of psychotic disorders associated with Alzheimer's disease. In addition, the company recently received the "Drug Clinical Trial Approval Notice" for its innovative Class 1 drug NH302 injection, allowing for clinical trials for acute pain.